Paradigm Biocapital Advisors LP Vaxcyte, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $1.95 Billion
- Q1 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 1,696,481 shares of PCVX stock, worth $62.1 Million. This represents 3.28% of its overall portfolio holdings.
Number of Shares
1,696,481
Previous 1,422,787
19.24%
Holding current value
$62.1 Million
Previous $116 Million
45.0%
% of portfolio
3.28%
Previous 4.44%
Shares
5 transactions
Others Institutions Holding PCVX
# of Institutions
340Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$446 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$441 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$431 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$364 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$235 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.17B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...